Eradication treatment for <i>Pseudomonas aeruginosa</i> infection in adults with bronchiectasis: a systematic review and meta-analysis.
Journal Information
Full Title: Eur Respir Rev
Abbreviation: Eur Respir Rev
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Pulmonary Medicine
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflict of interest: M. Shteinberg reports grants or contracts from GSK and Trudell pharma; consulting fees from AstraZeneca, Boehringer Ingelheim, Dexcel, Kamada, Synchrony Medical, Trumed, and Zambon; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AstraZeneca, Boehringer Ingelheim, and Kamada; support for attending meetings or travel from Boehringer Ingelheim, AstraZeneca, and Kamada; participation on a Data Safety Monitoring Board or Advisory Board for Bonus Biotherapeutics, Boehringer Ingelheim, and AstraZeneca; leadership or fiduciary role in other board, society, committee, or advocacy groups with Israeli Pulmonology Society, Israeli Society for Tuberculosis and Mycobacterial Diseases, and EMBARC as unpaid management board member, and the European Respiratory Journal and Chest as an unpaid Editorial board member; and receipt of equipment, materials, drugs, medical writing, gifts or other services from Trudell Medical International. J.D. Chalmers reports grants or contracts from Grifols; consulting fees from Antabio, AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Grifols, Insmed, Janssen, Novartis, Pfizer, and Zambon; and leadership or fiduciary roles as Chair of European Respiratory Society (ERS) Bronchiectasis Guideline Task Force, Chief Editor of the European Respiratory Journal, and Chair of EMBARC Clinical Research Collaboration. All other authors have nothing to disclose."
"Support statement: EMBARC3 is funded by the European Respiratory Society through the EMBARC3 clinical research collaboration. EMBARC3 is supported by project partners Armata, AstraZeneca, Boehringer Ingelheim, Chiesi, CSL Behring, Grifols, Insmed, Janssen, Lifearc, and Zambon. J.D. Chalmers is supported by the GlaxoSmithKline/Asthma and Lung UK Chair of Respiratory Research and a Scottish Senior Fellowship from the Chief Scientist Office. Funding information for this article has been deposited with the Crossref Funder Registry."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025